TVGN at $2.54 looks interesting and maybe a AH play? Shelf offering or dilution could thrash it though.
TVGN ... Travogen?/ Let me look it up./ Did you notice Shoals today? It really held up. It's not for the feint hearted but this could be a huge winner. Of course if Trump wins all solar may be in trouble tough to say. It won't help but there are several moving parts with Shoals that add up to a good investment. Today ENPH missed bad sector was rocked. Aside from Van's pick all the top losers were solar yet here we have Shoals 5 days down 1.5%... That's how you spot a bottom. Citi on Shoals Technologies Group (NASDAQ: SHLS), upgrading the stock from Sell to Neutral and adjusting the price target to $5.50, up from the previous $5.00. The reassessment follows the developments in the company's patent infringement case, where the Administrative Law Judge (ALJ) recommended a limited exclusion order. * Co received Blattner and top 10 Engineering, Procurement, and Construction (EPC) Master Service Agreements (MSAs). Shoals Technologies' recent investor day has also played a role in resetting market expectations, providing guidance and a cautious outlook on utility-scale growth. The analyst notes that the primary downside risk for the company is the potential launch of an Alternate Design (AD) product by Voltage, which may occur soon and would not be affected by the exclusion order. Shoals Technologies Group::::Mizuho Securities maintained its Outperform rating and $8.00 price target for the company, despite recent legal challenges. Piper Sandler increased Shoals' price target to $10.00, citing factors such as resolution of patent litigation and a refined commercial strategy. However, the firm later reduced its price target to $8.00, expressing confidence in the company's management and a 30% EBITDA margin target. TD Cowen reiterated a Buy rating and a price target of $11.00, reflecting confidence in Shoals' strategic plan to diversify and expand its market reach. Truist Securities adjusted its outlook for the company, reducing the price target from $10.00 to $8.00 while maintaining a Buy rating. Shoals Technologies reported a year-over-year decrease in second-quarter revenue by 16.7% to $99.2 million due to project delays. Despite this, the company secured a Master Supply Agreement with Blattner, expected to generate approximately $636 million in revenue through 2027. In legal developments, Shoals Technologies emerged victorious in a patent infringement case against Voltage, LLC. This victory could potentially strengthen its market and intellectual property positions.
why would this guy sell at $1.62? Oct 17 https://www.streetinsider.com/SEC+Filings/Form+4+Tevogen+Bio+Holdings+For:+Oct+17+Filed+by:+Flomenberg+Neal/23854935.html
Huuuuummmmmmmmm This could be big Ted. Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days Provided byGlobeNewswire Oct 21, 2024 1:56pm WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) --Tevogen Bio(“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, reported last week that Chief Scientific Officer (CSO) Dr. Neal Flomenberg sold shares. Tevogen's Chief Financial Officer, Kirti Desai, clarified that the sale was made solely to satisfy the payment of tax obligations relating to the vesting of restricted stock units and was not made at the discretion of the CSO. Other officers, the Chief Executive Officer, the Chief Financial Officer, and the Chief Commercial Officer, who hold more than 75% of total outstanding shares in aggregate, have already paid taxes when shares were granted and have no further obligation to make similar share sales. Additionally, none of the company’s officers have decreased their holdings since the company’s inception. In a related update, Tevogen Bio recently released top-line revenue projections for its oncology therapeutic area, anticipating $1 billion in revenue in the launch year for its lead product candidate, with a cumulative 5-year estimate ranging between $10 billion and $14 billion. The company plans to release similar revenue forecasts for its non-oncology therapeutic areas in the coming days. "The leadership team’s retention of 100% of their equity reflects our collective confidence in the company’s potential," said Tevogen CEO Dr. Ryan Saadi. "With over half a billion shares traded on the open market last week, I am deeply grateful for the public’s unprecedented support of Tevogen’s innovative business model."
WTF This has RAIN written all over it.... Other officers, the Chief Executive Officer, the Chief Financial Officer, and the Chief Commercial Officer, who hold more than 75% of total outstanding shares in aggregate
Additionally, none of the company’s officers have decreased their holdings since the company’s inception. This simply is not true. Look at the first link